R&D | March 26, 2026
Zealand Pharma launches major US research hub in Cambridge, Massachusetts
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
The Cambridge hub is designed to expand Zealand Pharma’s global research capabilities
The move comes as China rapidly expands its capabilities in the pharmaceutical sector, particularly in licensing and drug development
The company said the move applies to all doses and reflects its commitment to making its medicines more affordable for patients
Asahi Kasei Pharma receives worldwide exclusive rights for the research, development, manufacturing, and marketing of the active ingredients
Under the deal, Quiver will receive an undisclosed advance payment and research support
Merck is currently conducting approximately 80 Phase 3 studies, and the company expects more than 20 new growth drivers over next several years, almost all with blockbuster potential
The NDA filing is supported by results from the phase III evERA Breast Cancer study
Each company will share operational data with Evinova, feeding the platform’s AI engines to provide benchmarks and actionable insights, aiming to speed up trials while maintaining top-tier patient care
The drug targets relapsed or refractory primary central nervous system lymphoma, a rare and aggressive form of non-Hodgkin lymphoma
The FDA’s Center for Biologics Evaluation and Research (CBER) cited Moderna’s choice of a licensed standard-dose flu vaccine as the comparator in its Phase 3 trial, saying it “does not reflect the best-available standard of care.”
Subscribe To Our Newsletter & Stay Updated
